[
    [
        {
            "time": "",
            "original_text": "复星医药：子公司复宏汉霖已向港交所提交上市申请",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "港交所",
                    "上市申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：子公司复宏汉霖已向港交所提交上市申请",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "复星医药：子公司复宏汉霖今日已向香港联交所提交上市申请",
            "features": {
                "keywords": [
                    "复星医药",
                    "复宏汉霖",
                    "香港联交所",
                    "上市申请"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "复星医药：子公司复宏汉霖今日已向香港联交所提交上市申请",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业周报:仿制药高毛时代过去,集中度提升将催生新巨头",
            "features": {
                "keywords": [
                    "医药生物",
                    "仿制药",
                    "集中度",
                    "新巨头"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "医药生物行业周报:仿制药高毛时代过去,集中度提升将催生新巨头",
                "Correlation": 5,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 8,
                "Entity_Density": 3,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-07-30",
            "original_text": "「A+H」临床合同研究机构（CRO）生物医药企业泰格医药将于8月7日在联交所挂牌，这是继药明康德、康龙化成后国内第三家CRO机构，其拟募资107亿港元（13.8亿美元），为2020年截止7月30日亚洲生物医药公司IPO规模最大项目。",
            "features": {
                "keywords": [
                    "泰格医药",
                    "CRO",
                    "联交所",
                    "IPO",
                    "募资"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "「A+H」临床合同研究机构（CRO）生物医药企业泰格医药将于8月7日在联交所挂牌，这是继药明康德、康龙化成后国内第三家CRO机构，其拟募资107亿港元（13.8亿美元），为2020年截止7月30日亚洲生物医药公司IPO规模最大项目。",
                "Correlation": 7,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "药明康德今日杀入港股，未盈利生物医药股有点慌？",
            "features": {
                "keywords": [
                    "药明康德",
                    "港股",
                    "生物医药",
                    "未盈利"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "药明康德今日杀入港股，未盈利生物医药股有点慌？",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "东方红睿玺基金经理高位抓牛尾，投资僵化忽视风险",
            "features": {
                "keywords": [
                    "东方红睿玺",
                    "基金经理",
                    "投资僵化",
                    "忽视风险"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "东方红睿玺基金经理高位抓牛尾，投资僵化忽视风险",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 2,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        }
    ]
]